Last Updated: 11/06/2026

Enara Bio

Oxford

Founded 2016

Cancer immunotherapies targeting novel antigens from the dark genome

Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter.

Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel antigens, while another platform is used to develop bispecific T cell engagers.

Its lead programme, ENA101, is entering first-in-human studies targeting the DARKFOX antigen.

Enara has a partnership with Boehringer Ingelheim for cancer vaccine development.

Biopharma Oncology Immunology Drug Discovery

T Cell Therapy Antibody Discovery

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page